Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000

Jack Delaney, The Motley Fool

Sat, August 29, 2026 at 10:00 PM GMT+3 4 min read

ALKS -3.05%

Christian Todd Nichols, SVP and Chief Commercial Officer of Alkermes (NASDAQ:ALKS), reported a sale of 7,576 shares of the company on Aug. 17, 2026, according to a recent SEC Form 4 filing.

Transaction summary

Transaction value based on SEC Form 4 weighted average sale price ($49.23); post-transaction value based on Aug. 17, 2026, market close ($49.85).

Key questions

What is the significance of the Rule 10b5-1 plan for this transaction?
The sale was conducted under a trading plan adopted on May 15, 2026, which established a predetermined schedule for the disposal three months before the trade was executed.
How much direct equity does Christian Todd Nichols retain in the company?
Following this transaction, the executive continues to hold approximately 102,000 shares directly, representing an insider ownership stake of 0.06%.
What was the market valuation of the security at the time of the sale?
The shares were sold at a weighted average price of $49.23, while the stock was valued at $49.85 at the market close on the day of the transaction.
How does this sale compare to the insider's total holdings?
The liquidation of 7,576 shares reduced the reporting owner's direct position from 109,769 shares to 102,193 shares, reflecting routine portfolio management.

Company Overview

Company Snapshot

Alkermes develops and commercializes proprietary pharmaceutical products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I disorder, and other neurological conditions, generating revenue through the sale of these commercial products and pipeline candidates in development.
The company operates a biopharmaceutical business model focused on research, development, and commercialization of therapeutic solutions that address unmet medical needs in neuropsychiatric and neurological disorders across multiple geographic markets.
Alkermes serves healthcare providers, patients, and healthcare systems in the United States, Ireland, and internationally, with a primary focus on treating patients with serious mental illness and substance use disorders.

Alkermes is a Dublin-headquartered biopharmaceutical company with a market capitalization of $7.9 billion and TTM revenues of $1.7 billion, positioning it as a significant player in the neuropsychiatric therapeutics space. The company maintains a diversified portfolio of commercial products and clinical-stage candidates, with a strategic focus on addressing high-prevalence conditions including opioid dependence, alcohol use disorder, and schizophrenia. Alkermes' competitive differentiation is anchored in its proprietary drug delivery technologies and sustained focus on underserved patient populations in mental health and addiction medicine.

What this transaction means for investors

Alkermes is off to a strong start in 2026. For the six months ended June 30, it reported $888.9 million in revenue, an increase from $697.2 million in the prior-year period. The stock price has also performed well, climbing 63.6% over the last 12 months. In comparison, the S&P 500 is up 19.3% in the same period. For Nichols, this was a pre-planed transaction, so it appears to be just selling to take some profits off the table after the stock has performed so well. Although he sold approximately 7,500 shares, he still directly holds more than 102,000 shares. Selling the amount of shares he did doesn't raise any alarm bells, and as it was a pre-planned sale, this shouldn't worry shareholders.

Analysts are typically bullish on what's ahead for Alkermes. Of the 17 covering the stock, 71% rate it a buy, 24% a hold, and 6% a sell, according to CNN. Among those analysts, the median one-year price target is $59, representing a 24.4% gain from today's price. The highest price target in the group is $72, while the lowest is $38.

Should you buy stock in Alkermes Plc right now?

Before you buy stock in Alkermes Plc, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alkermes Plc wasn't one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $440,710!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,335,252!*

That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul.

See the 10 stocks »

*Stock Advisor returns as of August 29, 2026.

Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alkermes Plc. The Motley Fool has a disclosure policy.

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000 was originally published by The Motley Fool